Abstract: Infections caused by Hepatitis C Virus (HCV) 
I. Introduction
Hepatitis C virus (HCV) causes hepatitis which, like other forms of viral hepatitis leads to inflammation of the liver and damage the liver cells. Itis a major cause of morbidity and mortality throughout the world. More than 185million people are infected with HCV worldwide, out of which 350,000 die each year. [1] Prevalence of anti-HCV in general population of India is approximately 1% of which 80% have detectable HCV RNA. [2] HCV is a 40-60nm enveloped single stranded positive sense RNA virus with 9400 base pair genome which was identified as the cause of non-A non-B hepatitis in 1989. It belongs to genus Hepacivirus in family Flaviviradae. There are 6 genotypes (1-6); genotype 3 is most common in India followed by genotype 1. The treatment modality for hepatitis C virus (HCV) infection has evolved substantially with the introduction of highly effective HCV protease inhibitors. These new compounds can cure more than 90% cases of HCV infections.
Natural History: HCV infections can present as an acute hepatitis, but more commonly leads to chronic hepatitis and chronic liver disease. Acute HCV hepatitis usually is asymptomatic. Symptomatic acute HCV infections usually have a mild clinical course and rarely lead to hepatic failure. But as spontaneous viral clearance is very low, about 60-80% cases of acute infections develop chronic infection; 20-30% of chronic infections develop cirrhosis and among those with cirrhosis, 1-4% develops hepatocellular carcinoma (HCC) per year. [3] It differs from other chronic viral infections in that it can be cured by treatment. There are different strains of the hepatitis C virus which influence the way the virus replicates in the body, the course of the disease and the response of the disease to treatment. There is currently no vaccine against hepatitis C.
Transmission:
The hepatitis C virus is usually transmitted through close contact with the blood of an infected person but in many cases, it is not possible to trace the source of the infection. Blood transfusions have been a significant source of hepatitis C infection before 1992.Transmission can also occur through intravenous drug use, tattooing, sexual intercourse. There is also risk of transmission to a baby during pregnancy or childbirth.
Symptoms: Acute hepatitis C symptoms Only a small proportion of people infected with the hepatitis C virus develop acute hepatitis. Symptoms include loss of appetite, nausea, tiredness, fever, abdominal pain and jaundice. It is usually a mild illness from which most people recover within four to eight weeks. Some people infected with the hepatitis C virus will rid their bodies of it completely but majority of the cases the virus remains in the body. These people are referred to as chronic carriers. Because most of the people infected with the hepatitis C virus do not develop the acute illness, they are not aware that they are chronic carriers. However, theytransmit the virus to other people.
Chronic hepatitis C symptoms
Chronic carriers of hepatitis C are at risk of chronic liver disease, which causes progressive damage to the liver. Symptoms of chronic liver disease may not manifest for many years. Early symptoms include mild fatigue, a feeling of being unwell, and alcohol intolerance. Serious complications of chronic liver disease, such as cirrhosis may take more than 20 years to develop after infection with the virus. People with cirrhosis may also develop liver failure or hepatocellular carcinoma.
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Whom to test for HCV:
Identification of those with active HCV infection is the most crucial step in treatment and prevention of HCV. HCV testing is recommended in select populations and it is based on proven benefits of care and treatment in reducing the risk of hepatocellular carcinoma and all-cause mortality.
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2.Risk behaviours:
Injection-drug use (current or ever); Intranasal illicit drug use 3.Risk exposures:Long-term haemodialysis (ever);getting a tattoo in an unregulated setting;healthcare, emergency medical, and public safety workers after needle sticks, sharps, ormucosal exposures to HCV-infected blood;Children born to HCV-infected women; Prior recipients of transfusions or organ transplants, including persons who were notified that they received blood from a donor who later tested positive for HCVinfection,received a transfusion of blood or blood components, or underwent an organ transplantbefore July 1992, received clotting factor concentrates produced before 1987 4.Other medical conditions: HIV infection,unexplained chronic liver disease and chronic hepatitis including elevated alanineaminotransferase.
Recommendations for HCV testing:
A) An anti-HCV test is recommended for HCV testing and if the result is positive, current infection should be confirmed by a sensitive RNA test. B) Among persons with a negative anti-HCV test who are suspected of having liver disease, testing for HCV RNA or follow-up testing for HCV antibody is recommended if exposure to HCV occurred within the past 6 months; testing for HCV RNA can also be considered in persons who are immunocompromised. C) Prior to initiation of HCV therapy, quantitative HCV RNA testing is necessary to document the baseline level of viremia, because the degree of initial viral decline is a crucial marker of the effectiveness of treatment. D) Among persons suspected of re-infection after previous spontaneous or treatment-related viral clearance, initial HCV-RNA testing is recommended because an anti-HCV test is expected to be positive.
Diagnosis
Hepatitis C may be suspected in a back ground of vague symptoms of being unwell with abnormal liver function. A blood test for hepatitis C antibodies determines whether a patient has been exposed to the virus and further blood test to confirm the presence of the actual virus in the blood. Quantitative HCV RNA testing is recommended prior to the initiation of antiviral therapy to document the baseline level of viremia (baseline viral load). Testing for HCV genotype is recommended to guide selection of the most appropriate antiviral regimen. If found to have positive results for anti-HCV test and negative results for HCV RNA by PCR, persons should be informed that they do not have evidence of current (active) HCV). Persons with current (active) HCV infection should receive education and interventions aimed at reducing progression of liver disease and preventing HCV transmission toothers. It is recommended to Abstinence from alcohol, evaluation for other conditions which accelerate liver fibrosis, including HBV and HIV infections, Vaccination against hepatitis A and hepatitis B, evaluation for advanced fibrosis using liver biopsy, imaging, or non-invasivemarkers in all persons with HCV.
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